EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Evaluation of the efficacy of sulbactam combination therapy for monomicrobial and polymicrobial pulmonary infections caused by multidrug-resistant Acinetobacter baumannii

Liangfei Peng, Xuemei Yang, Xiaohua Qiu, Li Wang, Ling Chen, Jiachen Wei, Chuwei Jing, Xiancheng Wu, Wen Li, Danni Wang, Qian Qian iD, Wenkui Sun iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.03355-24 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Liangfei Peng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Sulbactam, Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Major Project of Jiangsu Health Vocational College, The Open Project of Jiangsu Health Development Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy in treatment of monomicrobial versus polymicrobial Acinetobacter baumannii (mono-AB vs poly-AB) pulmonary infections remains unclear. This study mainly investigated the efficacy of sulbactam combination regimens against mono-AB and poly-AB pulmonary infections. A multicenter retrospective study of adult patients who received sulbactam or cefoperazone/sulbactam for multidrug-resistant A. baumannii (MDRAB) between August 2021 and July 2023 was conducted. The outcomes of 7-day microbiological efficacy and 14-day clinical efficacy were measured. A total of 366 patients were enrolled, including 75 mono-AB patients. Among the 291 poly-AB cases, 82 patients were co-infected with Pseudomonas aeruginosa and 76 patients with Klebsiella pneumoniae . All A. baumannii isolates exhibited multidrug resistance. The antibiotics demonstrating the highest sensitivity against these isolates were polymyxins and tigecycline, with sensitivity rates of 91.25% and 71.63%, respectively. In the multivariable analysis, patients receiving sulbactam-based treatment for poly-AB pulmonary infections exhibited significantly higher microbial clearance of A. baumannii compared with those with mono-AB infections. Microbial efficacy analysis of A. baumannii co-infection with K. pneumoniae or P. aeruginosa showed similar results to overall poly-AB infections. Sulbactam doses ≥ 8 g/day showed the best microbiological and clinical efficacy. Sulbactam combined with tigecycline and/or polymyxins demonstrated significantly better microbiological efficacy compared with sulbactam alone. Sulbactam combined with polymyxins resulted in better microbiological and clinical efficacy than when combined with tigecycline. In conclusion, patients with poly-AB lung infections exhibit a higher microbial clearance rate of A. baumannii following treatment compared with those with mono-AB infections. A daily dose ≥8 g sulbactam may be optimal for treating MDRAB pneumonia. The combination of sulbactam and polymyxins demonstrates significant advantages over other sulbactam-containing regimens in terms of microbiological and clinical efficacy. IMPORTANCE This is the first multicenter retrospective study to investigate the efficacy of sulbactam combination regimens in the treatment of monomicrobial and polymicrobial AB-related pulmonary infections. Our study found that patients receiving sulbactam-based treatment for poly-AB pulmonary infections exhibited significantly higher microbial clearance of A. baumannii compared with those with mono-AB infections. Microbial efficacy analysis of A. baumannii co-infection with K. pneumoniae or P. aeruginosa showed similar results to overall poly-AB infections. These findings are significantly important for further analyzing the potential mechanisms underlying the differences in efficacy between antimicrobial treatments for monomicrobial and polymicrobial infections, as well as for optimizing clinical antimicrobial combination strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulbactamAcinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsCoinfectionHumansMaleRetrospective StudiesFemaleDrug Resistance, Multiple, BacterialMiddle AgedAgedDrug Therapy, CombinationPseudomonas aeruginosaTreatment OutcomeMicrobial Sensitivity TestsAdultKlebsiella pneumoniaePseudomonas InfectionsAged, 80 and overCefoperazone

Stichwörter der Autor:innen

Acinetobacter baumanniicombination therapyefficacymultidrug-resistantpolymicrobial pulmonary infectionsulbactam

Substanzen

SulbactamAnti-Bacterial AgentsCefoperazone

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital With Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China.
  • Department of Emergency and Critical Care Medicine, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China.
  • Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
  • Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
  • Department of Respiratory and Critical Care Medicine, BenQ Medical Center, Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Qian Qian, Wenkui Sun

Förderung

  • The Major Project of Jiangsu Health Vocational College
  • The Open Project of Jiangsu Health Development Research Center

Zitieren

APA

Peng, L., Yang, X., Qiu, X., Wang, L., Chen, L., Wei, J., Jing, C., Wu, X., Li, W., Wang, D., Qian, Q., & Sun, W. (2025). Evaluation of the efficacy of sulbactam combination therapy for monomicrobial and polymicrobial pulmonary infections caused by multidrug-resistant Acinetobacter baumannii. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03355-24

Vancouver

Peng L, Yang X, Qiu X, Wang L, Chen L, Wei J, et al. Evaluation of the efficacy of sulbactam combination therapy for monomicrobial and polymicrobial pulmonary infections caused by multidrug-resistant Acinetobacter baumannii. Microbiology Spectrum. 2025. doi:10.1128/spectrum.03355-24

BibTeX
@article{Peng2025,
  author = {Peng, Liangfei and Yang, Xuemei and Qiu, Xiaohua and Wang, Li and Chen, Ling and Wei, Jiachen and Jing, Chuwei and Wu, Xiancheng and Li, Wen and Wang, Danni and Qian, Qian and Sun, Wenkui},
  title = {Evaluation of the efficacy of sulbactam combination therapy for monomicrobial and polymicrobial pulmonary infections caused by multidrug-resistant Acinetobacter baumannii},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.03355-24}
}
Kostenlos starten →